TrivarX Limited (ASX:TRI)
0.0110
+0.0005 (4.76%)
At close: Sep 12, 2025
TrivarX Revenue
In the fiscal year ending June 30, 2025, TrivarX had annual revenue of 1.13M AUD with 27.02% growth. TrivarX had revenue of 278.00 in the half year ending June 30, 2025, a decrease of -5.12%.
Revenue
1.13M
Revenue Growth
+27.02%
P/S Ratio
6.04
Revenue / Employee
188.16K
Employees
6
Market Cap
6.82M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 1.13M | 240.15K | 27.02% |
Jun 30, 2024 | 888.83K | -71.62K | -7.46% |
Jun 30, 2023 | 960.45K | -45.00K | -4.48% |
Jun 30, 2022 | 1.01M | -258.10K | -20.43% |
Jun 30, 2021 | 1.26M | 338.28K | 36.56% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 23.73B |
Pro Medicus | 212.98M |
Cochlear | 2.34B |
Sonic Healthcare | 9.65B |
Ramsay Health Care | 17.79B |
Ansell | 3.06B |
Telix Pharmaceuticals | 1.01B |
Mesoblast | 26.23M |